GSK has presented positive mid-stage trial data for a potential new blockbuster liver drug only a day after suffering a setback with an important cancer treatment.
The British drugs company said the results of a study of bepirovirsen for the treatment of chronic hepatitis B could help to lead to a breakthrough in finding a “functional cure” for what researchers called an “ancient disease”.
Chronic hepatitis B is described as a “major global health threat” that can lead to liver complications, including cirrhosis and cancer. An estimated 296 million people globally live with the disease and almost 900,000 people die a year.
Bepirovirsen is a key asset in GSK’s mid-stage drugs pipeline and at a pivotal shareholder event in June last year, ahead of a
© Times Newspapers Limited 2022.